Ontology highlight
ABSTRACT:
SUBMITTER: Fehniger TA
PROVIDER: S-EPMC3217400 | biostudies-literature | 2011 Nov
REPOSITORIES: biostudies-literature
Fehniger Todd A TA Larson Sarah S Trinkaus Kathryn K Siegel Marilyn J MJ Cashen Amanda F AF Blum Kristie A KA Fenske Timothy S TS Hurd David D DD Goy Andre A Schneider Stephanie E SE Keppel Catherine R CR Wagner-Johnston Nina D ND Carson Kenneth R KR Bartlett Nancy L NL
Blood 20110921 19
Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 ( ...[more]